Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD ...

The target action date for Rexulti in combination with sertraline to treat patients with post-traumatic stress disorder, ...

Kerenida is currently approved to slow the progression chronic kidney disease associated with type 2 diabetes.

Health plans will need to navigate a difficult financial environment caused by increased healthcare costs and potential ...

Fianlimab plus Libtayo demonstrated persistent and significant clinical activity in patients with advanced melanoma.